IHH-4 Cells
USD 800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Información general
| Descripción | The IHH-4 cell line is derived from papillary thyroid carcinoma (PTC), the most prevalent form of thyroid cancer, which frequently exhibits aggressive characteristics including invasion and metastasis. IHH-4 has been utilized in numerous studies focused on elucidating the molecular mechanisms underpinning PTC progression. This cell line is particularly noted for its role in studies investigating epithelial-mesenchymal transition (EMT), a process that enhances the invasive potential of cancer cells. For example, it has been shown that IHH-4 cells, along with other PTC lines, express elevated levels of matrix metalloproteinase-9 (MMP-9), a protease that plays a critical role in degrading the extracellular matrix and facilitating tumor invasion and metastasis. Inhibition of MMP-9 in IHH-4 cells was found to reduce EMT markers and hinder cell migration and invasion. Research involving the IHH-4 cell line has also examined the role of transcription factors such as T cell factor 4 (TCF4) and long non-coding RNAs (lncRNAs) in PTC. Studies have highlighted that TCF4 is overexpressed in IHH-4 cells and can regulate the expression of the lncRNA HCP5, which in turn modulates several microRNAs related to tumor progression. Knockdown of TCF4 in IHH-4 cells was shown to decrease cell proliferation and invasion, suggesting that TCF4 is a pivotal regulator of oncogenic pathways in PTC. Overall, IHH-4 serves as a valuable model for studying molecular and cellular pathways related to thyroid cancer, particularly those that drive cancer cell invasion, metastasis, and resistance to therapies. The insights gained from research using IHH-4 contribute to the development of potential therapeutic strategies for combating aggressive thyroid cancers. |
|---|---|
| Organismo | Human |
| Tejido | Thyroid gland |
| Enfermedad | Thyroid gland papillary carcinoma |
| Lugar de metástasis | Left cervical lymph node |
| Sinónimos | IHH4 |
Características
| Edad | 75 years |
|---|---|
| Género | Male |
| Origen étnico | Japanese |
| Morfología | Epithelial-like |
| Propiedades de crecimiento | Adherent |
Datos normativos
| Referencia | IHH-4 (Cytion catalog number 305448) |
|---|---|
| Nivel de bioseguridad | 1 |
| NCBI_TaxID | 9606 |
| N.º de acceso de Cellosaurus | CVCL_2960 |
| Estado de los OGM | GMO-S1: This human thyroid papillary carcinoma cell line (IHH-4) contains undefined stable modifications consistent with tumor-derived immortalization. No infectious virus is produced. This classification applies only within Germany and may differ elsewhere. |
Datos biomoleculares
| Perfil mutacional | Mutation: AKT1, p.Glu17Lys (c.49G>A), heterozygous; Mutation: BRAF, p.Val600Glu (c.1799T>A), heterozygous; Mutation: CREBBP, p.Trp592Ter (c.1776G>A), heterozygous; Mutation: CRLF2, p.Trp255Ter (c.765G>A), heterozygous; Mutation: EP300, p.Arg1312Ter (c.3934C>T), heterozygous; Mutation: RAC1, p.Asp11Glu (c.33C>G), heterozygous; Mutation: TERT, c.1-124C>T (c.228C>T) (C228T), heterozygous |
|---|
Manejo
| Medio de cultivo | 1 to 1 mixture of Dulbecco's modified Eagle's medium (Cytion article number 820300a) and RPMI1640 medium (Cytion article number 820700a) |
|---|---|
| Suplementos | Supplement the medium with 10% heat-inactivated FBS |
| Reactivo de disociación | Accutase |
| Subcultivo | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Medio de congelación | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Descongelación y cultivo de células |
|
| Atmósfera de incubación | 37°C, 5% CO2, humidified atmosphere. |
| Condiciones de envío | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Condiciones de almacenamiento | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Control de calidad y análisis molecular
| Esterilidad | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificado de análisis (CoA)
| Número de lote | Tipo de certificado | Fecha | Número de catálogo |
|---|---|---|---|
| 305448-301025 | Certificado de análisis | 05. Dec. 2025 | 305448 |